Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use KRESLADI safely and effectively. See full prescribing information for KRESLADI. KRESLADI (marnetegragene autotemcel) suspension for intravenous infusion Initial U.S. Approval: 2026
Medication labelWhy this: Advisory · dailymed-other
KRESLADI is indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant. This indication is approved under accelerated approval based on increase in neutrophil CD18 and CD11a surface expression [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- generic_name
- marnetegragene autotemcel
- product_names
- MARNETEGRAGENE AUTOTEMCEL
- ndc
- 83537-034, 83537-034-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en